Drug Profile
Zevorcabtagene autoleucel - CARsgen
Alternative Names: Anti-BCMA CAR T cell therapy - CARsgen; BCMA-redirected autologous T cells-CARsgen; CAR BCMA T-cell therapy-CARsgen; CAR-BCMA T Cell Infusion; CT-053 - CARsgen; Zevor-celLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple myeloma
Most Recent Events
- 15 Mar 2024 Launched for Multiple myeloma (Second-line therapy or greater) in China (IV) as of March 2024 - First Global Launch (CARsgen pipeline, March 2024)
- 23 Feb 2024 Registered for Multiple myeloma (Second-line therapy or greater) in China (IV) - First Global Approval
- 12 Dec 2023 Updated efficacy and safety data from the phase Ib/II LUMMICAR study 1 in Multiple myeloma released by CARsgen